Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

Bristol Myers’ (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) posted strong growth in the second quarter.Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.It is approved in the United States for the treatment...